# Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review

## TL;DR

This review finds that faster biological aging is linked to higher risk and worse outcomes in liver disease tied to metabolic dysfunction.

## Contribution

The paper systematically reviews evidence linking biological aging to MASLD/NAFLD risk and progression.

## Key findings

- Accelerated biological aging is associated with higher odds of MASLD/NAFLD and increased fibrosis severity.
- Higher biological aging predicts greater all-cause mortality in individuals with MASLD.
- Biological aging mediates some effects of environmental toxicants and interacts with genetic risk factors in MASLD.

## Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a growing global health burden. Geroscience posits that accelerated biological aging is a key driver of chronic disease. We systematically reviewed the evidence to define the role of biological aging (BA) across the MASLD disease spectrum.

A systematic literature search of PubMed/MEDLINE and Embase was conducted from inception through August 2025 for observational studies in adults assessing validated BA measures (phenotypic age, Klemera–Doubal method, Homeostatic Dysregulation, epigenetic clocks, telomere length) and MASLD outcomes. A narrative synthesis was performed following SWiM guidelines because of substantial methodological heterogeneity.

Nineteen studies were included. BA was operationalized using clinical composite clocks (KDM-BA, PhenoAge, Homeostatic Dysregulation), epigenetic clocks, leukocyte telomere length, homeostatic dysregulation indices, and one machine-learning BA metric. Accelerated BA generally referred to BA higher than expected for chronological age or shorter telomere length. Across large cross-sectional studies, individuals with accelerated BA had higher odds of MASLD/nonalcoholic fatty liver disease (NAFLD), and in prospective cohorts, higher BA at baseline predicted increased hazards of incident NAFLD after multivariable adjustment, suggesting BA functions as an upstream integrator of risk rather than only a consequence of liver disease. Accelerated BA was also associated with greater fibrosis burden and with higher all-cause mortality among people with MASLD. Several studies indicated that BA mediates part of the effect of environmental toxicants on MASLD and acts as an effect modifier, with higher risk observed when accelerated BA co-occurs with unfavorable genetic profiles or environmental exposures. Mendelian randomization analyses supported a potential causal role of cellular aging in liver fibrogenesis.

Across 19 observational studies, accelerated biological aging (assessed using clinical composite indices, epigenetic clocks, and telomere length) was consistently associated with higher MASLD/NAFLD risk, greater fibrosis severity, and higher mortality. These findings support BA as potentially a clinically relevant risk integrator in MASLD spectrum diseases. However, heterogeneity in BA measures and disease definitions limits comparability and highlight the need for harmonized BA measures in longitudinal studies.